TPST Tempest Therapeutics Inc

Price (delayed)

$2.01

Market cap

$44.66M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.72

Enterprise value

$32.7M

Millendo Therapeutics is a clinical-stage biopharmaceutical company primarily focused on developing novel treatments for endocrine diseases where current therapies do not exist or are insufficient. Millendo seeks to create distinct ...

Highlights
The EPS has grown by 35% YoY and by 10% from the previous quarter
The net income has grown by 15% YoY
The equity has soared by 88% YoY but it has contracted by 23% from the previous quarter
The quick ratio is down by 28% since the previous quarter

Key stats

What are the main financial stats of TPST
Market
Shares outstanding
22.22M
Market cap
$44.66M
Enterprise value
$32.7M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.16
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$28.29M
EBITDA
-$26.24M
Free cash flow
-$26.53M
Per share
EPS
-$1.72
Free cash flow per share
-$1.19
Book value per share
$0.93
Revenue per share
$0
TBVPS
$2
Balance sheet
Total assets
$44.38M
Total liabilities
$23.75M
Debt
$20.37M
Equity
$20.63M
Working capital
$22.81M
Liquidity
Debt to equity
0.99
Current ratio
3.13
Quick ratio
3.02
Net debt/EBITDA
0.46
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-79%
Return on equity
-232.4%
Return on invested capital
-115.7%
Return on capital employed
-84%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

TPST stock price

How has the Tempest Therapeutics stock price performed over time
Intraday
-29.47%
1 week
-33.66%
1 month
-38.53%
1 year
57.03%
YTD
-54.32%
QTD
-48.59%

Financial performance

How have Tempest Therapeutics's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$29.55M
Net income
-$29.76M
Gross margin
N/A
Net margin
N/A
The net income has grown by 15% YoY
The company's operating income rose by 13% YoY

Growth

What is Tempest Therapeutics's growth rate over time

Valuation

What is Tempest Therapeutics stock price valuation
P/E
N/A
P/B
2.16
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 35% YoY and by 10% from the previous quarter
The equity has soared by 88% YoY but it has contracted by 23% from the previous quarter
The price to book (P/B) is 27% higher than the 5-year quarterly average of 1.7

Efficiency

How efficient is Tempest Therapeutics business performance
The ROE has plunged by 51% YoY but it has grown by 18% from the previous quarter
TPST's return on invested capital is up by 25% year-on-year but it is down by 8% since the previous quarter
The company's return on assets fell by 23% YoY but it rose by 3.8% QoQ

Dividends

What is TPST's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for TPST.

Financial health

How did Tempest Therapeutics financials performed over time
The company's total assets is 87% higher than its total liabilities
The quick ratio is down by 28% since the previous quarter
The current ratio has declined by 27% since the previous quarter and by 4.6% year-on-year
The equity has soared by 88% YoY but it has contracted by 23% from the previous quarter
The debt to equity has dropped by 50% year-on-year but it is up by 29% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.